News Release
2022
-
April 27, 2022
Submission of New Drug Application for Fostamatinib, an oral spleen tyrosine kinase inhibitor, in Japan
-
April 25, 2022
Confirmation of Positive CHMP Opinion for GnRH Antagonist "Linzagolix" in Europe
-
April 22, 2022
Kissei Announces New President and COO
-
March 31, 2022
Results of Phase III Clinical Study of "CAROGRA® Tablets" Conducted in Japan for Treatment of Ulcerative Colitis (AJM300/CT3) Published in The Lancet Gastroenterology & Hepatology
-
March 28, 2022
"CAROGRA® Tablets", Approved in Japan for Treatment of Ulcerative Colitis - The World-First Orally Available α4 Integrin Antagonist -
-
February 7, 2022
Update on EU marketing authorisation process for "Linzagolix" for the reatment of uterine fibroids
-
January 7, 2022
Positive Topline Results from Japanese Phase III Clinical Study (double-blind period) of Difelikefalin (MR13A9) in Hemodialysis Patients with Pruritus
